Skip to main content
. 2010 Feb 14;16(6):673–682. doi: 10.3748/wjg.v16.i6.673

Table 2.

Phase III trials of gemcitabine doublets

Phase III trial Combination OS (mo) P PFS (mo) P
Berlin et al[12] (n = 322) Gem + FU 6.7 0.09 3.4 0.022
Gem 5.4 2.2
Herrmann et al[16] (n = 319) Gem + Cap 8.4 0.234 4.8 0.0207
Gem 7.2 4.0
Heinemann et al[19] (n = 219) Gem + Cisplatin 7.6 0.12 5.3 0.053
Gem 6.0 3.1
Colucci et al[20] (n = 107) Gem + Cisplatin 6.9 0.48 5 0.048
Gem 4.6 2
Louvet et al[23] (n = 326) GemOx 9.0 0.13 5.8 0.04
Gem 7.1 3.7
Poplin et al[11] (n = 824) GemOx 5.7 0.09 2.7 0.15
Gem 4.9 2.6
Gem FDR 6.2 3.5
Rocha Lima et al[27] (n = 342) IRINOGEM 6.3 0.789 3.5 0.352
Gem 6.6 3.0
O'Reilly et al[29] (n = 339) Gem + Exatecan 6.7 0.52 3.9 0.22
Gem 6.2 4.0

FU: Fluorouracil.